Recent Blog Posts

View Post: Pulmonary Disease, Chronic Obstructive Clinical Trial: A Study to ...
4 Nov 2009
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD). The Purpose of this study is to assess the efficacy and safety of three .... History of Exacerbations: A documented history (e.g., medical record verification) of at least one COPD exacerbation in the 12 months prior to Visit 1 that required either oral corticosteroids, antibiotics and/or hospitalization. ...
View Blog: Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r...

---

View Post: Respiratory Research
Full text
The bioavailability and airway ... ...
View Blog: The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial ... Although these combinations both contain an ICS and a LABA, differences exist with regard to the pharmacokinetic and pharmacodynamic properties of both components, such as the oral bioavailability and clearance, volume of distribution and speed of

---

View Post: EuroPharma Today: Boehringer Finds COPD Exacerbation Studies Can ...
23 Sep 2009 by Sean  
Boehringer Finds COPD Exacerbation Studies Can Be An Exasperating Experience. Private German Big Pharma Boehringer Ingelheim is seeking to expand its indication for Spiriva HandiHaler (tiotropium inhalation powder) to include its use against exacerbation of chronic obstructive ... Forest Laboratories recently inked a deal with Nycomed as its commercialization partner for Daxas (roflumilast), a promising oral COPD drug, which recently turned up positive Phase II data. ...
View Blog: EuroPharma Today - http://www.europharmatoday.com/

---

View Post: FDA accepts NDA for mometasone furoate/formoterol fumarate ...
23 Jul 2009
This fixed-dose therapy combines the active ingredients of an inhaled corticosteroid, Asmanex (mometasone furoate), with a long-acting beta2-agonist, Foradil (formoterol fumarate inhalation powder), administered via a single metered-dose inhaler. ... July 20, 2009. Nycomed announced the submission of a New Drug Application (NDA) to the FDA for Daxas (roflumilast) as a once-daily oral treatment for symptomatic chronic obstructive pulmonary disease (COPD). ...
View Blog: Latest articles from MPR News - http://www.empr.com/

---

View Post: Advair Diskus (Fluticasone Propionate) Drug Information: Uses ...
19 Jun 2008
Disposable purple device with 60 blisters containing a combination of fluticasone propionate (100, 250, or 500 mcg) and salmeterol (50 mcg) as an oral inhalation powder formulation. An institutional pack containing 14 ...... HPA Axis Effects: Short-cosyntropin stimulation testing was performed both at Day 1 and Endpoint in 101 patients with COPD receiving twice-daily ADVAIR DISKUS 250/50, fluticasone propionate powder 250 mcg, salmeterol powder 50 mcg, or placebo. ...
View Blog: RxList - News and Features - http://www.rxlist.com/script/main/hp.asp

---

View Post: FDA Safety Changes: Advair Diskus and Vfend
20 Aug 2008
The FDA has approved revisions to the safety labeling for fluticasone propionate plus salmeterol xinafoate inhalation powder and voriconazole tablets, injection, and oral suspension. ... Fluticasone Plus Salmeterol Inhalation Powder (Advair Diskus) May Obfuscate Signs of Pneumonia in Patients With COPD. On April 30, the FDA approved safety labeling revisions for fluticasone propionate plus salmeterol xinafoate inhalation powder (Advair Diskus; GlaxoSmithKline) to ...
View Blog: Medscape Pulmonary Medicine Headlines - http://www.medscape.com/pulmonarymedicine

---

View Post: FDA Safety Changes: Visicol and Advair Diskus
21 Jun 2006
The FDA has approved revisions to the safety labeling for sodium phosphate monobasic monohydrate plus sodium phosphate dibasic anhydrous tablets and fluticasone plus salmeterol inhalation powder. ... twice-daily use in the maintenance treatment of asthma in patients aged 4 years and older. The 250-µg/50-µg formulation is indicated for the twice-daily treatment of airflow obstruction in patients with chronic obstructive pulmonary disease associated with chronic bronchitis . ...
View Blog: Medscape Gastroenterology Headlines - http://www.medscape.com/gastroenterology

---

View Post: USPharmacist.com > Management Strategies in Stable COPD
26 Jan 2009
When educating patients about COPD, it is important to include the following items: smoking cessation, pharmacologic therapy, self-management skills, and proper use of inhalation devices. ..... Advair Diskus (fluticasone propionate) package insert. Research Triangle Park, NC:GlaxoSmithKline; 2007. 41. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. ...
View Blog: Untitled - http://www.uspharmacist.com/home/

---

View Post: Successful Treatment of Previously Uncontrolled Adult Asthma with ...
20 Sep 2007 by Gawchik, S. M  
Over the next 10 months while receiving fluticasone and salmeterol, the patient experienced 4 asthma exacerbations requiring oral corticosteroid treatment. An exacerbation in October 2000 resulted in an ED visit. At that time, her PEF was 220 ..... Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma 1998;35:273-9.[Medline]; Erickson SR, Horton A, Kirking DM. ...
View Blog: Annals of Pharmacotherapy current issue - http://www.theannals.com/

---